Shattuck Labs (STTK)
(Delayed Data from NSDQ)
$10.59 USD
+0.81 (8.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.60 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Shattuck Labs, Inc. [STTK]
Reports for Purchase
Showing records 1 - 20 ( 26 total )
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Mid-2024 Brings Abundant Data Readouts Across Various Indications For SL-172154
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
Early BD Interest From Ono Highlights Shattuck''s Construction Capabilities of Multifunctional Compounds
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
SL-172154 Focus Piece; All Eyes On Upcoming Readouts in Frontline MDS/AML; Potential First to Market Opportunity
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
Key Data Updates Across SL-172154 Program Set the Stage For 1H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
154 Hitting Nice Stride; Strong Early Promise in Frontline TP53+ AML and HR-MDS; Next Readout Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
ASH Presentation Highlights Encouraging Initial Profile For SL-17254 in r/r AML/HR-MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Encouraging Early Readouts Continue; Positive Interim Data From SL-172154 in Phase 1 PROC Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
First Look at SL-172154 Shows Encouraging Signs of Anti-Leukemic Activity; Full Presentation at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; All Eyes on SL-172154 as Key Data Readouts Expected 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
SL-172154 Potential Demonstrated in PROC Phase 1a Dose-Escalation Study at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
SL-172154 Data Establish Promising Foothold in PROC; Full Presentation at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; All Eyes on SL-172154´s Key Data Readouts for PROC and AML/HR-MDS in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
CD20-GADLEN Preclinical Anti-Tumor Activity Profile Strengthens at AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
Gamma Delta T Cell Therapy: A Small (But Mighty) Subset of T Cells Ready for Battle in I/O Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Upcoming Multiple Inflection Points for SL-172154; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
Food for Thought: CD47 Blockade Emerges as a Next- Generation Checkpoint Inhibitor Strategy; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
Following a Year of Execution, Three Key Clinical Readouts on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Shattuck Labs, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Multiple SL-172154 Readouts on Track During 1H23; GADLEN Update at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J